AGDr. Allen P. Green, MDBack to Journal
December 28, 2024|1 min read

The AMBAR Study: Part 1 - Understanding Plasma Exchange and Key Results

A deep dive into the landmark AMBAR clinical trial that demonstrated therapeutic plasma exchange can slow cognitive decline in Alzheimer's disease by 50-75%.

AG
Dr. Allen P. Green
Associate Medical Director, Global Apheresis

Share this article

Twitter / XLinkedInEmail
AG

Dr. Allen P. Green, MD

Associate Medical Director at Global Apheresis. Board-Certified Clinical Pathologist specializing in therapeutic apheresis for longevity, health optimization, and preventative medicine.

More from the Journal

February 15, 2026

My Journey to Global Apheresis

How I joined the pioneering team advancing therapeutic apheresis for longevity and health optimization.

Read More →February 10, 2025

The Jersey PFAS Crisis: Why Government-Recommended 'Bloodletting' Isn't Enough

New Jersey's PFAS contamination crisis exposes thousands to forever chemicals. The government recommends blood donation as treatment — but there's a far more effective medical solution.

Read More →February 4, 2025

The Hidden Risk of Weight Loss: How Forever Chemicals Get Released During Fat Loss

When you lose weight, fat cells release stored PFAS and other forever chemicals into your bloodstream. Understanding this hidden risk is critical for anyone on a weight loss journey.

Read More →
Back to All Posts